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128Objective: It is uncertain whether mitral valve replacement is really inferior to mitral valve repair for the
treatment of chronic ischemic mitral regurgitation. This multicenter study aimed at providing a contribution
to this issue.
Methods: Of 1006 patients with chronic ischemic mitral regurgitation and impaired left ventricular function
(ejection fraction<40%) operated on at 13 Italian institutions between 1996 and 2011, 298 (29.6%) underwent
mitral valve replacement whereas 708 (70.4%) received mitral valve repair. Propensity scores were calculated
by a nonparsimonious multivariable logistic regression, and 244 pairs of patients were matched successfully
using calipers of width 0.2 standard deviation of the logit of the propensity scores. The postmatching median
standardized difference was 0.024 (range, 0-0.037) and in none of the covariates did it exceed 10%.
Results: Early deaths were 3.3% (n¼ 8) in mitral valve repair versus 5.3% (n¼ 13) in mitral valve replacement
(P ¼ .32). Eight-year survival was 81.6%  2.8% and 79.6%  4.8% (P ¼ .42), respectively. Actual freedom
from all-cause reoperation and valve-related reoperation were 64.3% 4.3% versus 80% 4.1%, and 71.3%
 3.5% versus 85.5% 3.9 in mitral valve repair and mitral valve replacement, respectively (P<.001). Actual
freedom from all valve-related complications was 68.3%  3.1% versus 69.9%  3.3% in mitral valve repair
and mitral valve replacement, respectively (P ¼ .78). Left ventricular function did not improved significantly,
and it was comparable in the 2 groups postoperatively (36.9% vs 38.5%, P ¼ .66). At competing regression
analysis, mitral valve repair was a strong predictor of reoperation (hazard ratio, 2.84; P<.001).
Conclusions:Mitral valve replacement is a suitable option for patients with chronic ischemic mitral regurgita-
tion and impaired left ventricular function. It provides better results in terms of freedom from reoperation with
comparable valve-related complication rates. (J Thorac Cardiovasc Surg 2013;145:128-39)Earn CME credits at
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Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CIMR ¼ chronic ischemic mitral regurgitation
HR ¼ hazard ratio
IQR ¼ interquartile range
LV ¼ left ventricular
LVEF ¼ left ventricular ejection fraction
MR ¼ mitral regurgitation
MVP ¼ mitral valve plasty
MVR ¼ mitral valve replacement
PS ¼ propensity score
SVD ¼ structural valve degeneration
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Dand leaflet tethering in the presence of a structurally normal
valve and subvalvular apparatus, with or without annular di-
latation.1 Left ventricular dysfunction may affect up to 20%
of patients with CIMR, and it carries a poorer prognosis.1,2
The optimal management of patients with CIMR remains to
be established.2,3-5 The benefit of mitral valve plasty (MVP)
compared with mitral valve replacement (MVR) has been
shown convincingly in patients affected by degenerative
mitral regurgitation (MR), but such an advantage remains
controversial in the presence of CIMR,2,3-10 particularly
in case of concurrent LV dysfunction.11,12
Published series on long-term results of mitral valve sur-
gery in CIMR patients, however, have also included patients
affected by regurgitation secondary to idiopathic cardiomy-
opathy or to degenerative disease, or by acute regurgitation
resulting from papillary muscle rupture, or they have been
carried out with limited heterogeneous patient cohorts,
making conclusive interpretation unfeasible.2,4-6 Therefore,
a multicenter, 15-year, retrospective, propensity score (PS)-
matched analysis of a robust patient cohort was designed to
elucidate comparative effectiveness ofMVP andMVR in as-
sociation with coronary artery bypass grafting (CABG) and
in the presence of LV dysfunction. Careful patient selection
was carried out purposefully to focus on a homogeneous pa-
tient population, eliminating some common confounding
factors characterizing published series on the matter, and
assessing early and long-term postoperative outcomes.METHODS
Patient Cohort and Data Collection
Thirteen Italian centers participated in the study. Data were collected
from patient charts for preoperative, operative, and hospital admittance de-
tails, and through direct or telephone interview with survivors, with rela-
tives, with general practitioners, or with hospital doctors in the case of
patients hospitalized for any cause after surgery. Patients were followed
up according to each individual institutional protocol.
Data refer to patients with CIMR and LV ejection fraction
(LVEF)<40% undergoing CABG procedure associated with MVP with
downsizing ring annuloplasty or MVR between 1996 and 2011. ChronicThe Journal of Thoracic and Caischemic MR was defined according to the following criteria: (1) prior
myocardial infarction>16 days, (2) 70% or greater stenosis of at least 1
coronary vessel, (3) a corresponding regional wall motion abnormality,
and (4) type I/IIIb leaflet dysfunction following Carpentier’s classification
with or without annular dilatation.
There were 1290 patients who met the CIMR definition. From this
patient population, 284 subjects were excluded because of emergency
surgery, repeat operation, LV reconstruction/reshaping, partial band/peri-
cardial annuloplasty, associated procedures other than ring annuloplasty
for MVP, residual MR 2þor paravalvular leak at hospital discharge, or
infective endocarditis, congenital valvular heart disease, rheumatic valvu-
lar disease, mitral stenosis, or associated valvular heart disease.
The final study cohort included 1006 patients; 708 patients (70.4%) un-
derwent MVP and 298 (29.6%) underwent MVR. All collected data were
sent to a core lab (Cardiovascular Research Unit, Ospedale Careggi, Flor-
ence, Italy) for analysis.
Ethical committee approval was waived because of the retrospective
analysis of the study according to the national law regulating observational
retrospective studies (law nr. 11960, released on July 13, 2004). Median
follow-up was 46.5 months (interquartile range [IQR], 26.6-69.0 months)
with a total of 1.942 years of evaluation. At the end of the follow-up
(July 31, 2011) the completeness of the follow-up was 94.8%. There
was no statistically significant difference in median length of follow-up be-
tween MVR and MVP (P ¼ .4).The definitions of valve-related complica-
tions followed guidelines for reporting morbidity and mortality after
cardiac valvular interventions.13
The decision to perform repair or replacement was at the surgeon’s dis-
cretion. Downsizing ring annuloplasty (2 sizes) was used in all patients
subjected toMVP. The ring sizewas determined by standard measurements
of the intertrigonal distance and anterior leaflet height. All patients under-
went complete revascularization.14
A successful repair was defined as a leaflet coaptation of 0.8 cm, MR
1, andmitral valve area>2 cm2 at transesophageal echocardiography per-
formed at the end of cardiopulmonary bypass.Echocardiography
Mitral regurgitation was graded following the American Society of
Echocardiography recommendations.15 Recurrence of MR was defined
as postoperative MR 2þ. All echocardiographic measurements followed
American Society of Echocardiography and European Society of Echocar-
diography guidelines.16Statistical Analysis
Estimation of PS and matching. Because of the significant im-
balances in baseline covariates between groups, we used PS matching.17 A
PS representing the probability of having MVR as opposed to MVP was
calculated for each patient by using a logistic regression model that iden-
tified variables associated independently with the type of surgical proce-
dure. Variables used in the model are shown in Tables 1 and 2. Pairs of
patients with MVP and MVR were matched using calipers of width 0.2
standard deviations of the logit of the PS.18 Covariate balance was mea-
sured using the standardized differences, by which an absolute standard-
ized difference >0.1 is suggested to represent meaningful covariate
imbalance.17 We accounted for the referring center by introducing in the
PS a categoric variable indicating the center.
Estimating treatment effects. Matched data were compared be-
tween MVP and MVR using the Wilcoxon signed-rank test and the
McNemar tests. Conditional logistic regression, which takes into account
the matched nature of the data,17 was used to identify predictors of early
mortality and to study the impact of the type of surgery on 30-day sur-
vival. Survival was determined by Kaplan-Meier methodology, and
curves were compared using the test described by Klein and Moesch-
berger.17 A Cox regression model with robust standard errors thatrdiovascular Surgery c Volume 145, Number 1 129
TABLE 1. Preoperative demographic, clinical, and echocardiographic data
Variable Repair (n ¼ 244) Replacement (n ¼ 244) Standardized difference
Age, y; mean  SD 66.0  7.1 66.1  8.0 0.036
Sex, male/female; n (%) 178/66 (72.9/27.1) 169/75 (69.2/30.8) 0.081
BSA, kg/m2; mean  SD 1.79  1.2 1.78  1.2 0.022
NYHA functional class, mean  SD 2.8  1.2 2.8  1.3 0.000
EuroSCORE, mean  SD 12.9  3.0 13.0  3.0 0.057
Family history, n (%) 131 (53.6) 137 (56.1) 0.050
Hypertension, n (%) 101 (41.3) 99 (40.5) 0.016
Diabetes mellitus, n (%) 89 (36.4) 86 (35.2) 0.025
COPD, n (%) 48 (19.6) 51 (20.9) 0.032
CRD, n (%) 68 (27.8) 72 (29.5) 0.037
CVD, n (%) 19 (7.7) 22 (9.0) 0.046
PVD, n (%) 12 (4.9) 13 (5.3) 0.018
AF, n (%) 30 (12.2) 32 (13.1) 0.027
Pulmonary hypertension, n (%) 21 (8.6) 23 (9.4) 0.028
History of CHF, n (%) 123 (50.4) 127 (52.0) 0.032
IABP, n (%) 78 (31.9) 75 (30.7) 0.025
MI localization, n (%)
Anterior 62 (25.5) 64 (26.2) 0.015
Lateral 60 (24.5) 61 (25.0) 0.011
Inferoposterior 122 (50.0) 119 (48.8) 0.024
Left main CAD 56 (22.9) 56 (21.9) 0.000
Echocardiographic data
LVEF,%; mean  SD 35.0  3.2 34.9  2.9 0.057
EDD, mm; mean  SD 55.0  7.2 55.2  6.9 1.075
ESD, mm; mean  SD 42.0  7.0 42.2  7.3 0.074
EDV, mL; mean  SD 173  25.3 173  27.2 0.000
ESV, mL; mean  SD 108  16.6 108  18.7 0.000
MR, grade; mean  SD 2.8  0.5 2.8  0.5 0.000
SD, Standard deviation; BSA, body surface area; NYHA, New York Heart Association; COPD, chronic obstructive pulmonary disease; CRD, chronic renal disease; CVD, cerebral
vascular disease; PVD, peripheral vascular disease; AF, atrial fibrillation; CHF, congestive heart failure; IABP, intra-aortic balloon pump; MI, myocardial infarction; CAD, cor-
onary artery disease; LVEF, left ventricular ejection fraction; EDD, end diastolic diameter; ESD, end systolic diameter; EDV, end diastolic volume; ESV, end systolic volume;MR,
mitral regurgitation.
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Daccounted for the clustering of matched pairs was used to identify predic-
tors of late death and to estimate the association of the type of surgery
with late mortality.17,18
Competing risk analysis was used to avoid overestimation of the inci-
dence of valve-related death, cardiac-related death, and valve-related com-
plications. First, a competing risk analysis with death as a competing event
was performed to assess the cumulative incidence curves of these nonfatal
events.13 The curves were also compared between the subgroups of pa-
tients. Then, a multivariable competing risk analysis was performed to
identify the independent risk factors for valve-related reoperation. We car-
ried out the competing risk regression model on the matched data, includ-
ing the treatment group indicator and all the covariates (the variables put
into the PS).
The influence of attempted valve repair, converted to replacement in the
same operation, was assessed in 2 ways. First, among propensity-matched
pairs, the variable attempted repair (crossover from repair to replacement
during the same operative session) was added to the multivariable models
used to compare valve repair versus replacement. Second, matched patients
were compared strictly as intent-to-treat. Furthermore, to take into account
the volume of the referring centers, we also add a volume categoric variable
into the model (400  600 operations/year, 600-1000 operations/year,
>1000 operations/year).
Analyses were performed using SAS, release 9.2 (SAS Institute, Cary,
NC), SPSS 12.0 (SPSS, Chicago, Ill), and Graph Pad Prism release 5
(Graph Pad Software Inc, La Jolla, Calif) statistical packages.130 The Journal of Thoracic and Cardiovascular SurgRESULTS
Overall Survival and Adverse Events
Thirty-seven patients (3.7%) died within 30 days and 137
patients (6.8%) died during the follow-up. Five- and 8-year
freedom from death were 75.5%  3.5% and 72.0% 
3.0%, respectively. Cumulative incidences of valve-
related death was 2.0% (95% confidence interval [CI],
1.6-2.7) whereas cumulative incidences of cardiac-related
death was 33.5% (95% CI, 27.4-41.3).
There were 148 valve-related reoperations (14.7%).
Causes of reoperationwere endocarditis in 24 patients, repair
failure in 106 patients, structural valve degeneration (SVD)
in 14patients, andparavalvular leak in 4 patients. Cumulative
incidences of valve-related reoperationwas 43.7% (95%CI,
30.1-50.0). Last, cumulative incidence of all valve-related
complications was 27.2% (95% CI, 21.9-34.7).Balance Diagnostics
Prematching baseline and operative data are shown in
Appendix 1 and Appendix 2, respectively. Prematchingery c January 2013
TABLE 2. Operative data
Variable
Repair
(n ¼ 244)
Replacement
(n ¼ 244)
Standardized
difference
CPB time, min; mean  SD 145  33 145  30 0.000
ACC time, min; mean SD 94  34 94  28 0.000
Distal anastomoses, n (%)
1 95 (38.9) 100 (40.9)
2-4 144 (59.0) 137 (56.2)
>4 5 (2.1) 7 (2.9)
Anastomoses/patient,
mean SD
2.2  0.2 2.2  0.2 0.000
Failed mitral valve repair,
n (%)
— 3 (1.2) —
Arterial graft/patient,
mean  SD
1.4  0.2 1.4  0.4 0.000
Ring size, n (%)
26 mm 66 (27.1) — —
28 mm 128 (52.5) — —
30 mm 31 (12.7) — —
32 mm 14 (5.7) — —
34 mm 3 (1.2) — —
36 mm 2 (0.8) — —
Mean  SD 28.0  3.4 — —
Median (IQR) 28 (26-28) — —
Ring type, n (%) — —
Carpentier Edwards
Classic
36 (14.7) — —
Carpentier Edwards
Physio
89 (36.5) — —
Carpentier Edwards
Physio II
74 (30.3) — —
Carpentier
McCarthyETlogix
8 (3.3) — —
Geoform — — —
St Jude Medical Seguin 4 (1.6) — —
St Jude Medical Rigid
Saddle
— — —
Sorin Memo 3D 33 (13.6) — —
Prosthesis size, n (%)
25 mm — 46 (18.8) —
27 mm — 87 (35.7) —
29 mm — 95 (38.9) —
31 mm — 11 (4.6) —
33 mm — 5 (2.0) —
Mean  SD — 27.7  1.8 —
Median (IQR) — 27 (27-29) —
Prosthesis type, n (%)
Biologic
Carpentier Edwards — 74 (57.3) —
Carpentier Edwards
MAGNA
— 4 (3.1) —
Sorin Mitroflow — 16 (12.5) —
Medtronic Hancock II — 5 (3.9) —
Medtronic Mosaic — 25 (19.4) —
St Jude Medical Epic — 5 (3.8) —
Labcor — — —
Moore — — —
(Continued)
TABLE 2. Continued
Variable
Repair
(n ¼ 244)
Replacement
(n ¼ 244)
Standardized
difference
Mechanical
St Jude Medical — 12 (10.4) —
Sorin Bicarbon — 9 (7.8) —
Carbomedics — 40 (34.9) —
ATS — 1 (0.8) —
On-X — 53 (46.1) —
Mitral leaflets preservation,
n (%)
None — 43 (37.4) —
Posterior — 24 (20.9) —
Both — 48 (41.7) —
CPB, Cardiopulmonary bypass; SD, standard deviation; ACC, aortic crossclamp;
IQR, interquartile range.
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Dstandardized differences exceeded 0.1 for 24 of the 31 cova-
riates (75.8%). Median prematching standardized differ-
ence was 0.170 (IQR, 0.105-0.369). The resultant
matched sample consisted of 244 matched pairs. Tables 1
and 2 show postmatching baseline and operative data. The
postmatching median standardized difference was 0.024
(IQR, 0-0.037), and in none of the covariates did it exceed
0.1 (Figure 1).Propensity-Adjusted Early and Long-Term Survival
The early (30-day) mortalities were 3.3% (n ¼ 8) for
MVP and 5.3% (n¼ 13) for MVR (P¼ .32). Multivariable
analysis revealed that independent predictors of operative
mortality were age, EuroSCORE 12, cardiopulmonary
bypass time, and aortic crossclamping time (Table 3),
whereas MVP provided no significant benefit over MVR.
During follow-up, 36 patients (14.7%) undergoing repair
and 41 patients (16.8%) in the replacement group died
(P ¼ .51; 1.8 patient/year for MVP and 1.5 patient/year
for MVR) Survival (Figure 2, A) for the MVP population
was 85.3%  2.6% at 5 years and 81.6%  2.8% at 8
years. Survival for the MVR population was 86.1% 
2.5% at 5 years and 79.6%  4.8% at 8 years (P ¼ .42).
Five- and 8-year survival for patients with LVEF>30%
(Figure 2, B) was 82.2%  2.6% and 78.5%  3% in
MVP and MVR (P ¼ .78), respectively, and 62.1% 
3.8% (P< .001 vs LVEF >30%) and 60.1%  3.0%
(P<.001 vs LVEF>30%) in patients with LVEF 30%
(P ¼ .82), respectively. In the MVR group, 8-year survival
was not significantly different between biologic and me-
chanical prostheses (81.4%  2.7% vs 77.8%  2.9%;
P ¼ .45).
Cumulative incidences of valve-related death (Figure 3,
A) were 1.3% (95% CI, 0.9-1.8) in MVP and 2.2% (95%
CI, 1.7-2.8) in MVR (P ¼ .1), whereas cumulative inci-
dences of cardiac-related death (Figure 3, B) were 22.1%
(95% CI, 18.3-27.1) and 20.2% (95% CI, 15.4-25.3) inrdiovascular Surgery c Volume 145, Number 1 131
FIGURE 1. Absolute standardized differences before and after propensity score matching comparing covariates values for patients undergoingmitral valve
repair or replacement (see text). CPB, Cardiopulmonary bypass; ACC, aortic crossclamp; EDD, end diastolic diameter; ESV, end systolic volume; ESD, end
systolic diameter; NYHA, New York Heart Association; EDV, end diastolic volume; CVD, cerebral vascular disease;MI, myocardial infarction; LVEF, left
ventricular ejection fraction; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; CRD, chronic renal disease; IABP, intra-
aortic balloon pump; CHF, congestive heart failure; BSA, body surface area; AF, atrial fibrillation; CAD, coronary artery disease.
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DMVP and MVR, respectively (P ¼ .55). Multivariate pre-
dictors of late mortality were age (hazard ratio [HR], 1.4;
P< .001), chronic renal failure (HR, 2; P< .001), and
LVEF (HR, 1.3; P ¼ .02). The type of mitral procedure
was not a significant predictor of late death (Table 3; HR,
1.0; P ¼ .5).
Propensity-Adjusted Long-TermAdverse Events and
Clinical Status
At follow-up, recurrence of mitral valve regurgitation in
MVP was 25% (61 patients, 4 with endocarditis). In MVR,
there were 4 patients with MR 2þbecause of a paravalvu-
lar leak (1.6%) and 11 because of bacterial endocarditis
(4.5%). In patients with MVR using tissue valves, 11 pa-
tients (6.4%) showed significant steno/insufficiency-type
structural valve degeneration (SVD).
Among propensity-matched patients, there were 65 mi-
tral valve reoperations, 39 in the MVP group (endocarditis,
n¼ 4; repair failure, n¼ 35) and 26 in the MVR group (19/
129 who received a bioprosthetic [SVD, n¼ 11; endocardi-
tis, n¼ 6; paravalvular leaks, n¼ 2] and 7/115 who received
a mechanical prosthesis [endocarditis, n ¼ 5; paravalvular
leaks, n ¼ 2]).
Cumulative incidences of valve-related reoperations
(Figure 3, C) were 46.2% (95% CI, 31.8-51.4) in MVP
and 31.3% (95% CI, 26.6-37.8) in MVR (P ¼ .01),
whereas the cumulative incidences of valve-related reoper-
ations in biologic and mechanical prostheses (Figure 3, D)
were 21.3% (95% CI, 16.8-26.6, P ¼ .007 vs MVP)132 The Journal of Thoracic and Cardiovascular Surgand 10.4% (95% CI, 6.5-15.1, P < .001 vs MVP),
respectively.
The cumulative incidence of SVD in patients<70 years
receiving a bioprosthetic valve (Figure 3, E) was 18.3%
(95% CI, 13.7-23.9), whereas in patients 70 years, it
was 9.2% (95% CI, 5.7-13.4, P<.001).
Last, cumulative incidences of all valve-related com-
plications (Figure 3, F) were 23.3% (95% CI, 17.8-29.0)
in MVP and 18.4% (95% CI, 13.6-23.7) in MVR
(P ¼ .38).
Multivariable competing risk regression (Table 3) identi-
fied age (HR, 2.4; P ¼ .03) and type of procedure (HR, 2.9;
P < .001) as multivariate predictors of valve-related
reoperation.
At follow-up, median NYHA functional class was 1.6
(IQR, 1.2-2.0) in MVP and 1.6 (IQR, 1.3-2.0) in MVR
(P > .9), respectively. Left ventricular ejection fraction
did not improve significantly from baseline in both groups
(MVP, 36.9  3.5 vs MVR, 38.5  3.3; P ¼ .66). Last, in
MVR patients, LVEF was higher in patients with total mi-
tral apparatus preservation (41.2  2.9) and isolated poste-
rior leaflet preservation (39.1 2.8) than in patients with no
leaflet preservation (36.3 2.6), although the difference did
not reach statistical significance (P ¼ .07).
DISCUSSION
Key Findings
Our study shows that, in patients affected by CIMR and
LV dysfunction, MVP and MVR have similar results inery c January 2013
FIGURE 2. A, Actuarial survival in mitral valve repair (MVP) and mitral
valve replacement (MVR). B, Actuarial survival in MVP and MVR by left
ventricular ejection fraction (LVEF).
TABLE 3. Univariable and multivariable analyses
Predictors
Univariable Multivariable
P
value
OR
(95% CI)
P
value
OR
(95% CI)
Predictors of early mortality
Age <.001 2.3 (1.7-2.9) <.001 2.1 (1.6-2.7)
Male sex .07 1.2 (0.8-1.9) .1 1.1 (0.7-1.9)
NYHA functional class .03 1.4 (0.8-2.1) .07 1.2 (0.8-1.8)
EuroSCORE  12 .01 1.8 (1.3-2.5) .009 2.0 (1.5-2.6)
Pulmonary hypertension .01 2.1 (1.8-2.7) .05 1.9 (1.3-2.5)
CRD .04 1.3 (0.9-1.7) .07 1.2 (0.8-1.7)
LVEF .07 1.1 (0.8-1.7) .09 1.1 (0.6-1.6)
MR .05 1.4 (0.9-1.8) .1 1.2 (0.7-1.7)
CPB time, min <.001 2.3 (1.9-2.9) <.001 2.3 (2.0-3.0)
ACC time, min <.001 2.0 (1.6-2.7) <.001 2.2 (1.9-2.8)
MVP vs MVR .08 1.1 (0.8-1.8) .1 1.1 (0.8-1.7)
Propensity score .03 1.3 (0.8-1.8) .1 1.1 (0.9-1.6)
Predictors of late mortality*
Age <.001 1.4 (1.3-2.2) <.001 1.4 (1.3-2.2)
COPD .06 1.2 (0.9-1.8) .2 1.1 (0.6-1.7)
CRD <.001 2.2 (1.9-2.7) <.001 2.0 (1.7-2.5)
LVEF .02 1.4 (1.0-1.9) .02 1.3 (1.0-1.8)
MVP vs MVR .08 1.1 (0.7-1.4) .2 1.1 (0.5-1.3)
Propensity score .006 1.4 (1.1-2.0) .5 1.05 (0.5-1.4)
Predictors of valve-related reoperationy
Age .005 2.4 (2.2-3.1) .03 2.4 (2.0-3.0)
MVP vs MVR <.001 2.9 (2.7-3.1) <.001 2.9 (2.5-3.2)
Propensity score .07 2.3 (1.9-2.6) .12 1.1 (0.8-1.5)
OR, Odds ratio; CI, confidence interval; NYHA, New York Heart Association; CRD,
chronic renal disease, LVEF, left ventricular ejection fraction; MR, mitral regurgita-
tion; CPB, cardiopulmonary bypass; ACC, aortic crossclamp; MVP, mitral valve
plasty; MVR, mitral valve replacement; COPD, chronic obstructive pulmonary dis-
ease. *Multivariable model with a robust variance estimate that accounts for cluster-
ing within matched pairs. yCompeting risk regression.
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ference was found between groups with regard to late LV
function, cardiac- and valve-related death, and patient func-
tional capacity. In contrast, patients who underwent MVP
exhibited a higher incidence of MR recurrence compared
with patients who underwent valve replacement. Last,
MVP resulted in being a strong predictor of valve-related
reoperation.Early and Late Survival
Hospital or 30-day mortality of patients with heteroge-
neous CIMR has been shown to be as low as 4% to 5%
in recent series.8,9 Our findings, although derived from
surgery carried out in selected and elective surgical
candidates, are in the same range, confirming that patient
with CIMR, even with LV impairment, may indeed
undergo MR correction and associated CABG with
favorable early outcome. In previous series, better early
survival in low-risk MVP patients compared with similar
MVR patients has been reported, whereas equal or even bet-
ter results with MVR have been documented in high-riskThe Journal of Thoracic and Cacases.11,12 More recent experiences have failed to detect
any substantial difference between the 2 surgical options
in terms of in-hospital or 30-day mortality, and are in accor-
dance with our observations.8-10 Furthermore, the exclusion
of emergency patients, reoperations, and complex cases
(mitral valve surgery þ CABG þ other associated
procedures) in our data analysis allowed us to focus on
the true impact of mitral surgery type and myocardial
revascularization on perioperative mortality in patients
with CIMR, confirming that only age, EuroSCORE-
related preoperative risk factors, and operative times act
as negative predictors for short-term prognosis, whereas
the application of MVP or MVR does not apparently exert
any inference.
In relation to late outcome, published series have pro-
vided a wide range of results. In 1995, Cohn and associ-
ates19 reported a 5-year survival of 56% and 91.5% in
MVP and MVR, respectively. More recent series have
shown a 5-year life expectancy that varies from 44% to
79.3% in MVP patients, and from 47% to 73.4% in
MVR subjects.6-9 This ample range may be explained
by the heterogeneity of patient cohorts that variably
included patients operated for acute MR, patients in
cardiogenic shock, patients with incomplete or without
CABG surgery, or patients with other associated cardiacrdiovascular Surgery c Volume 145, Number 1 133
FIGURE 3. A, Cumulative incidence plots depicting valve-related death. B, Cumulative incidence plots depicting cardiac-related death. C, Cumulative
incidence plots depicting valve-related reoperations. D, Cumulative incidence plots depicting valve-related reoperations in biological vs mechanical pros-
theses. E, Cumulative incidence plots depicting structural valve deteriorations. F, Cumulative incidence plots depicting all valve-related complications.
MVR, Mitral valve replacement; MVP, mitral valve plasty; BIO, biologic; MECH, mechanical.
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tients undergoing MVP or MVR electively with complete
myocardial revascularization, 8-year survival showed fa-
vorable results regardless the type of mitral valve surgery
and despite the presence of moderate impairment of LV
function. Our survival figures resembled the recent series
of Magne and colleagues,10 who reported an 8-year sur-
vival in propensity score-matched cohorts of 65% in134 The Journal of Thoracic and Cardiovascular SurgMVP patients versus 68% in MVR cases. In contrast,
Maltais and coworkers8 have reported overall survival
of 55% and 24% at 5 and 10 years, respectively, in pa-
tients with CIMR with ischemic cardiomyopathy
(LVEF <45%). Such a discrepancy with our data may
be explained, again, by the exclusion from our data
analysis of reoperations, emergency cases, and complex
operations, which accounted for 19%, 3.4%, 15%,ery c January 2013
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study of the Mayo Clinic.8
In our experience, cardiac- and valve-related mortality
were also similar between groups, and type of intervention
was not a significant predictor of late death.
Recurrence of Mitral Regurgitation and Need of
Reoperation
Concern has been raised about a high incidence of per-
sistent or recurrent MR following restrictive annuloplasty
in patients with CIMR. Postoperative recurrence rate of
moderate/severe MR has been shown to be as much as
33% of the patients at 6 months, or more than 70% at
5 years.20,21 In our study, MR occurred in 25% of MVP
patients in the long term, and repair was related directly
to higher likelihood of reoperation. Although predictors
of reappearance or deterioration of MR have been
related to preoperative features of mitral valve anatomic
features or to LV geometry and dimensions,14,22,23
suggesting which patients might be considered MVP
responders in CIMR, it seems unquestionable that, also
in the presence of intraoperative successful MVP,
recurrence of MR still represents a disappointing and not
unusual complication in patients with CIMR submitted
to mitral valve annuloplasty.
Replacing the mitral valve, however, does not confer, as
expected, long-lasting freedom from valve-related dys-
function and reoperation. With regard to the use of
MVR in CIMR, current opinion apparently favors the
use of tissue valves for the ease of preserving the mitral
leaflets and avoidance of postoperative anticoagulation-
related adverse events.3-5 Our findings, however, indicate
that, based on the rather favorable mid- and long-term
prognoses of these patients, bioprosthetic degeneration
might represent another potential shortcoming or compli-
cation to be confronted during the postoperative lifetime
of patient with CIMR who undergo MVR, although, ap-
parently, with a reduced rate compared with recurrent
MR in MVP patients.
Acute endocarditis was responsible for recurrent MR in
1.6% of MVP patients and in 4.5% of MVR subjects.
This aspect has been rarely addressed or reported in previ-
ous studies, although Grossi and associates12 showed a 3%
rate of acute valvular infection in patients who underwent
MVR, and Chan and colleagues9 found a 1.5% incidence
in their MVP patients. Further analysis is warranted to con-
firm the actual incidence of such an adverse event in pa-
tients with CIMR.
Impact of Surgery on Left Ventricular Function
A small improvement in LV function following MVP or
MVR and CABG for ischemic MR has been reported by
Calafiore and associates.22 In a recent study, no change in
postoperative LV function was observed in 18% of patientsThe Journal of Thoracic and Caoperated either with MVP or MVR, deteriorated LV con-
tractility was shown in 20% of MVP patients versus 16%
of MVR patients, and improved LV performance accounted
for less than one-third of patients in both surgical cohorts,
respectively.9 De Bonis and collaborators23 showed that
LV functional improvement could be achieved only in
50% of patients operated with successful MVP for ischemic
or dilated cardiomyopathy, and such a positive contractile
change was associated with LV reverse remodeling. Note-
worthy, in contrast to a variable effect as far as LV perfor-
mance or LV dimension is concerned, functional capacity
or quality of life appear to be improved substantially after
surgery in the long term in the majority of patients
with CIMR patients.4,22,23 Lack of improvement or
deterioration of LV contractile performance may have
several explanations, but surgery performed beyond the
point of no return of LV remodeling, further evolution of
coronary artery disease, and persistence or recurrence of
MR may all play a critical role.2,4
It is generally agreed that preserving the mitral–
ventricular continuity during MVR has a beneficial effects
in terms of early and long-term outcome.24 There is still
no definite evidence, however, about the superiority of bi-
leaflet sparing versus isolated posterior leaflet preservation
alone.4,24 In our experience, albeit limited by the inherent
bias of the study, a trend toward a beneficial effect of
chordal sparing MVR (62.6% of our patients) versus
severance of the annular ventricular continuity was
shown, with a greater, although not significant, benefit
regarding LV function when both MV leaflets were
maintained. Further studies are unquestionably warranted
to elucidate conclusively these peculiar aspects of MVR.
Limitations
This study has the well-known and relevant shortcomings
of a retrospective, multicenter, PS analysis. In addition,
other limitations must be pointed out. First, when perform-
ing a propensity-matched analysis, there is always a risk of
losing an important subgroup of patients that were not
matched. In this study, selection bias is introduced at the
time of decision to perform surgery because the decision
to performMVRmay be related to the complexity of the pa-
tient and the experience of the surgeon. Therefore, matched
repair patients might represent a sicker group of patients,
which in turn may potentially indicates that MVP is not
as good for a specific high-risk group of patients. Appropri-
ate and consistent patient matching, however, was achieved
effectively in a robust patient population. Furthermore, the
common heterogeneity of other similar published studies
was carefully addressed by strict patient selection criteria.
Second, this study is heterogeneous (several centers and
15 years’ inclusion time) and this takes into account when
examining our findings because the approach to functional
mitral valve insufficiency has changed during the past 15rdiovascular Surgery c Volume 145, Number 1 135
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Indeed after 15 years there might be more MR recurrence
and reoperation for valve degeneration compared with
a shorter follow-up. Fourth, there is no information about
tricuspid valve function, which may have been very impor-
tant in the setting of ventricular dilation. Fifth, we failed to
provide information on the excluded MVP patients with
more than 2þMR at discharge, which could have been of in-
terest and value for future interpretation.
Sixth, preoperative information about the exact mecha-
nisms and characteristics of preoperative MR and the postre-
pair mitral valve features (coaptation height and coaptation
depth, for instance) were not available in all patients, making
comparative investigations among pre-, intra-, and post-
operative mitral valve performance unfeasible. For this rea-
son, the objectives of this study were, exclusively, early and
late outcomes, and not determination of favorable or negative
predictors in relation to mitral valve-related preoperative
variables.
The patient population included subjects with coronary
artery disease, CIMR, and LV dysfunction. Information
about detection of myocardial viability was not available
in all patients, thereby impeding any further analysis in
this respect regarding the presence or absence of revascular-
ized viable myocardium on postoperative LV function. It is
likely, however, that these patients exhibited favorable con-
ditions for perioperative management and expected benefit
from myocardial revascularization.
In terms of surgical procedure, preservation of mitral
subvalvular apparatus was carried out in only 66% of pa-
tients, and was applied variably according to surgeons’
preference and indications. Furthermore, no detailed infor-
mation was available regarding mechanisms of recurrent
MR at follow up.
Last, postoperative data regarding LV diameters and vol-
umes related to the type of procedure and/or other factors
(leaflet preservation in MVR) were not included in this
study and will be object of a companion analysis.
CONCLUSIONS
Our retrospective, multicenter, PS-based study indicates
that MVP apparently did not confer any substantial benefit
compared with MVR in terms of early- and long-term sur-
vival, valve-related complication rates, and effects on LV
performance. In contrast, it exposes operated patients to
higher recurrence of MR and to higher reoperation rate.
Therefore, MVR appears to be a valuable surgical option
for patients with CIMR and LV dysfunction undergoing mi-
tral valve surgery and CABG. Nonetheless, SVD should be
taken into consideration when tissue valves are implanted,
based on a favorable postoperative life expectancy. An on-
going, randomized trial in patients with CIMR is paramount
for providing conclusive insight into the appropriate man-
agement of such an increasing patient population.25136 The Journal of Thoracic and Cardiovascular SurgWe gratefully acknowledge Mrs Judith Wilson for the
English revision of this article. Our heartfelt thanks to Prof
Eugene Blackstone for his suggestions about competing risk
regression.References
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DDiscussion
Dr Irving Kron (Charlottesville, Va). I must say I have a con-
flict of interest in that I am a primary investigator for the Cardio-
thoracic Surgical Network.
I would like to congratulate the authors on an outstanding paper.
They have been accurate and clear and discussed the issues with
such an analysis. They have done a database study of>1000 pa-
tients with CIMR. This is a retrospective study with propensity
matching. The findings were interesting. Patients with MVR had
a 3% mortality versus 5% for MVP, and this was not significant.
The 8-year survival was exactly the same. Based on these findings,
it would seem that MVR is certainly a reasonable strategy.
There are, however, difficulties with this assessment. First and
foremost, this is a retrospective study with little standardization
of the procedures or choice of repair versus replacement. In the re-
placement group, the majority of patients did not have chordal
sparing of both leaflets. The majority of patients were followed
less than 5 years, so prosthetic failure cannot truly be analyzed
at this point. But bottom line, this suffers all the issues of any ret-
rospective study, although this is an excellent attempt to give us an
answer to this clinical problem.
The Network study is a randomized study, and we have just
closed enrollment of 250 patients randomized to mitral repair vs
replacement. Of course, the issue is as the authors stated: Is repair
less risky versus the issues of later recurrence? So I believe the ran-
domized trial may give us an answer to this, but certainly not the
long-term follow-up at this point. I have two questions for the
authors.
The first is, could they predict which patients who had repairs
were likely to recur? They have a great data set. The second ques-
tion is whether, with longer follow-up, will there be more reopera-
tions for the prosthetic replacement group? Thank you very much
for an excellent effort.
Dr Parolari. Thank you so much, Dr Kron, for your questions.
For the first one, up to now the core lab is still investigating the
problem of prediction of mitral valve recurrence. The problem is
that this is a retrospective study, and the earliest cases date back
to about 15 years, and also the echocardiographic variables that
were collected in earlier cases were different than the ones thatThe Journal of Thoracic and Cawere collected in later ones. We know that this is one of the next
tasks to be addressed, but up to now I don’t have any data about
that.
The second question is the problem of reoperation on biopros-
thetic valves. I think the problem raised in our paper is the follow-
ing one.We have selected somehow lower risk patients becausewe
excluded reoperations, we excluded emergency cases, and we had
high survival rates. I mean both in the replacement and in the re-
paired valve groups, the estimated survival at 8 years was around
80%. If so, many patients with a bioprosthetic valve survive in the
long term, and we know that bioprosthetic valves may have prob-
lems at longer follow-up times. This is going to be an issue. And
probably we will see that, in the future, when longer follow-up
times are available, although up until now, the difference between
a patient who got a mechanical prosthesis and a patient who got
a bioprosthesis in terms of reoperation was not statistically
different.
Dr John D. Puskas (Atlanta, Ga). Thank you for your presen-
tation. You have really tackled a difficult problem and applied
a careful analysis of a large data set to that problem. One of the
challenges that Dr Kron mentioned is that this is a retrospective
study. One of the points of entry of bias into a retrospective study
is patient exclusion. You chose to exclude patients who left the
hospital and left the operating room with residual mitral regurgita-
tion after mitral repair for CIMR. If your study is to guide decision
making by surgeons, it seems to me that the decision is made well
prior to hospital discharge; the decision is made, in fact, prior to or
in the operating room whether to repair or replace the valve. Why
did you exclude patients who had an imperfect repair from your
analysis?
Dr Parolari. First of all, we excluded patients who had>1þ
grade mitral regurgitation at follow-up. We decided to do that be-
cause it is our practice, at least in past years, to leave no more
than 1þMR, and we don’t leave 2þMR or higher degrees if there
is not a good reason. Another reason why we excluded patients
with>1þMR is because many people are discussing the problem
concerning what group of patients to be compared. Some people
say—and even Dr Bolling, whom I see here, was already saying
that—that, in case of CIMR, you don’t have 2 groups to compare,
but you have 3. The first one is a good repair, the second is a bad
repair, and the third one is MVR. So we wanted to exclude the
worst repairs and just to compare only the good repairs with MVR.
Dr Steven F. Bolling (Ann Arbor, Mich). A very nice study on
a very vexing problem. You really have 2 groups. You have re-
placement and repair, and you must have 2 subgroups in your re-
pair group. Seventy-five percent of those patients got a good
repair and 25% got a bad repair with residual and recurrent MR,
and yet you blend them together to analyze their survival. That
can’t be valid. The 75% who had a good repair probably do better,
and the 25% bad repair dragged the survival average back down to
the same as replacement.
I have 2 questions for you. Reflecting on what Dr Kron said, in
the group of bad repairs, the 25%, did you identify anything that
led to a bad repair? And also, did you do analysis on these patients
in terms of their initial LV size, which may be a far more important
indicator of their long-term outcome as opposed to ejection
fraction?
Thank you. Very nice study.rdiovascular Surgery c Volume 145, Number 1 137
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cerning LV diameters and LV dimensions, in the beginning, the
LV end systolic diameter mean was 56 mm in the repair group
and 59 mm in the replacement group. However, the end diastolic
volume was 117 mL in both groups. We do not have, up to now,
predictors concerning the results of repairs. It was difficult for us
to decide what was a good repair and a bad repair at the begin-
ning because we were working on retrospective data and we just
could go back to the chart. So it is very difficult for us to answer
the question.
Dr Robert A. Dion (Genk, Belgium). I would like to insist on
the fact that when one attacks such a population one has to qualify
it. I mean, there is for sure a group of patients with preoperative LV
dimensions and LV volumes who are doing much better with 1 of
the 2 solutions. For instance, I believe that if the preoperative LV
end diastolic diameter much exceeds 65 mm, the patient is proba-
bly better off even with a replacement.
What I miss in your paper is that you should not only classify
the patients according to mitral valve repair versus replacement,
but qualify them according to the preoperative dimensions,APPENDIX 1. Preoperative demographic, clinical, and echocardiographic
Variable Repair (n ¼ 708)
Age, y; mean  SD 65.8  9.1
Sex, male/female; n (%) 537/171 (75.8/24.2)
BSA, kg/m2; mean  SD 1.79  0.2
NYHA functional class; mean  SD 2.5  1.1
EuroSCORE; mean  SD 13.5  3.4
Family history, n (%) 413 (58.3)
Hypertension, n (%) 354 (50.0)
Diabetes, n (%) 243 (34.3)
COPD, n (%) 147 (20.7)
CRD, n (%) 183 (25.8)
CVD, n (%) 65 (9.1)
PVD, n (%) 26 (3.6)
AF, n (%) 77 (10.8)
Pulmonary hypertension, n (%) 70 (9.8)
History of CHF, n (%) 371 (52.4)
IABP, n (%) 254 (35.8)
MI localization, n (%)
Anterior 159 (22.5)
Lateral 197 (27.8)
Inferoposterior 352 (49.7)
Left main CAD 154 (21.7)
Echocardiographic data, mean  SD
LVEF,% 35.8  2.9
EDD, mm 56.0  8.7
ESD, mm 42.5  7.7
EDV, mL 175  29.7
ESV, mL 112  19.2
MR, grade 2.8  0.5
SD, Standard deviation; BSA, body surface area; NYHA, New York Heart Association; COP
vascular disease; PVD, peripheral vascular disease; AF, atrial fibrillation; CHF, congestive
onary artery disease; LVEF, left ventricular ejection fraction; EDD, end diastolic diameter; E
mitral regurgitation.
138 The Journal of Thoracic and Cardiovascular Surgpreoperative volumes, postoperative incidence, and the rate re-
verse remodeling, because these parameters will deeply influence
the outcome, maybe even more than the type of procedure.
And finally let us say that you replace the valve with a biopros-
thesis and the patient benefits from a LV remodeling and survives
long enough for the bioprosthesis to degenerate. This patient now
faces a reoperation for a re-replacement of the mitral valve, which
might have been anticipated by a careful analysis of the preopera-
tive parameters, don’t you think?
Dr Parolari. Concerning the problem of the dimensions, Dr
Dion, I thank you for this question, the problem is that these
data were collected over a 15-year period of time and they were
retrospective. And concerning also the possible predictors of
that, it is very difficult for me to answer this question, but it will
be answered probably much better from the Cardiothoracic Sur-
gery Network in the currently running trial.
About bioprostheses, this is a big problem. We are still investi-
gating that. Hopefully next year, probably Dr Roberto Lorusso,
who is the principal investigator, will have more answers about
that that we don’t have now. Thank you.data in the unmatched population
Replacement (n ¼ 298) Standardized difference
70.3  8.0 1.538
204/94 (68.4/31.6) 0.155
1.75  0.2 0.089
2.9  1.2 0.373
13.9  3.2 0.220
169 (60.0) 0.642
119 (39.9) 0.007
122 (40.9) 0.213
75 (25.1) 0.128
92 (30.7) 0.108
92 (11.7) 0.403
20 (6.7) 0.008
40 (13.3) 0.384
33 (11.0) 0.644
179 (60.0) 0.433
119 (39.9) 0.469
72 (24.1) 0.744
72 (24.1) 0.090
154 (51.6) 0.819
66 (22.1) 0.901
36.6  3.8 0.437
59.0  6.0 1.106
44.2  6.3 0.642
173  28.8 0.369
109  20.1 0.677
3.0  0.5 0.282
D, chronic obstructive pulmonary disease; CRD, chronic renal disease; CVD, cerebral
heart failure; IABP, intra-aortic balloon pump; MI, myocardial infarction; CAD, cor-
SD, end systolic diameter; EDV, end diastolic volume; ESV, end systolic volume;MR,
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APPENDIX 2. Operative data in the unmatched population
Variable
Repair
(n ¼ 708)
Replacement
(n ¼ 298)
Standardized
difference
CPB time, min; mean SD 158  36 138  29 3.356
ACC time, min; mean SD 117  39 101  30 2.105
Distal anastomoses, n (%)
1 133 (18.8) 45 (15.1)
2-4 560 (69.1) 242 (81.2)
>4 15 (2.1) 11 (3.7)
No. of anastomoses/patient,
mean  SD
2.7  0.4 2.9  0.5 0.298
Failed mitral valve repair,
n (%)
— 11 (3.6) —
No. of arterial grafts/
patient, mean  SD
1.4  0.2 1.6  0.4 0.365
Ring size, n (%)
26 mm 185 (26.1) — —
28 mm 362 (51.2) — —
30 mm 99 (13.9) — —
32 mm 34 (4.8) — —
34 mm 15 (2.2) — —
36 mm 13 (1.8) — —
Mean  SD 28.2  2.1 — —
Median (IQR) 28 (26-28) — —
Ring type, n (%)
Carpentier Edwards
Classic
76 (10.7) — —
Carpentier Edwards
Physio
278 (39.9) — —
Carpentier Edwards
Physio II
193 (27.3) — —
Carpentier
McCarthyETlogix
27 (3.8) — —
Geoform 13 (1.8) — —
St Jude Medical Seguin 11 (1.5) — —
St Jude Medical Rigid
Saddle
5 (0.7) — —
Sorin Memo 3D 105 (14.8) — —
Prosthesis size, n (%)
25 mm — 40 (13.4) —
27 mm — 102 (34.2) —
29 mm — 115 (38.6) —
31 mm — 29 (9.7) —
33 mm — 12 (4.1) —
Mean  SD — 28.1  1.9 —
Median (IQR) — 29 (27-29) —
Prosthesis type, n (%)
Biologic
Carpentier Edwards — 92 (54.2) —
Carpentier Edwards
MAGNA
— 7 (4.1) —
Sorin Mitroflow — 21 (12.4) —
Medtronic Hancock II — 8 (4.7) —
Medtronic Mosaic — 30 (17.6) —
St Jude Medical Epic — 10 (5.8) —
Labcor — 1 (0.6) —
Moore — 1 (0.6) —
(Continued)
APPENDIX 2. Continued
Variable
Repair
(n ¼ 708)
Replacement
(n ¼ 298)
Standardized
difference
Mechanical
St Jude Medical — 16 (12.6) —
Sorin Bicarbon — 12 (9.4) —
Carbomedics — 43 (33.6) —
ATS — 1 (0.7) —
On-X — 56 (43.7) —
Mitral leaflets preservation,
n (%)
None — 47 (36.7) —
Posterior — 29 (22.6) —
Both — 52 (40.7) —
CPB, Cardiopulmonary bypass; SD, standard deviation; ACC, aortic crossclamp;
IQR, interquartile range.
Lorusso et al Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery c Volume 145, Number 1 139
A
C
D
